We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+10.67%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$735M
AUM Growth
–
Cap. Flow
+$730M
Cap. Flow
% of AUM
99.32%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$78.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$65.1M |
| 3 |
CELG
Celgene Corp
CELG
|
+$61.4M |
| 4 |
Biogen
BIIB
|
+$41M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$35.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.4% |
| 2 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$163B
| $77.1M | 10.48% |
+1,504,712
| New | +$78.4M |
|
|
2
Regeneron Pharmaceuticals
REGN
$77.4B
| $62.9M | 8.56% |
+279,759
| New | +$65.1M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $59.6M | 8.11% |
+1,020,092
| New | +$61.4M |
|
|
4
Biogen
BIIB
$30.7B
| $41.3M | 5.62% |
+191,983
| New | +$41M |
|
5
Vertex Pharmaceuticals
VRTX
$122B
| $36.3M | 4.93% |
+454,164
| New | +$33.4M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $34.3M | 4.66% |
+371,329
| New | +$35.8M |
|
7
Puma Biotechnology
PBYI
$402M
| $31.6M | 4.29% |
+711,800
| New | +$25.1M |
|
8
Perrigo
PRGO
$1.43B
| $24.5M | 3.33% |
+202,607
| New | +$24M |
|
|
ONXX
9
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $22M | 3% |
+253,856
| New | +$23.4M |
|
10
Amgen
AMGN
$209B
| $19.7M | 2.69% |
+200,143
| New | +$20.8M |
|
|
WCRX
11
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
| $15.6M | 2.12% |
+782,797
| New | +$13.3M |
|
12
Viatris
VTRS
$20.7B
| $15.1M | 2.06% |
+488,209
| New | +$14.6M |
|
|
SHPG
13
DELISTED
Shire pic
SHPG
| $14.7M | 1.99% |
+154,153
| New | +$14.5M |
|
14
Merck
MRK
$321B
| $13.8M | 1.87% |
+310,858
| New | +$13.9M |
|
|
CBST
15
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $12.8M | 1.75% |
+265,972
| New | +$13.1M |
|
|
AKRX
16
DELISTED
Akorn Inc
AKRX
| $12.7M | 1.72% |
+935,758
| New | +$13.2M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $12.5M | 1.7% |
+197,241
| New | +$11.6M |
|
18
Verastem
VSTM
$536M
| $12.3M | 1.67% |
+73,743
| New | +$8.88M |
|
19
Teva Pharmaceuticals
TEVA
$41.2B
| $12.2M | 1.66% |
+311,476
| New | +$12.1M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $11.5M | 1.57% |
+91,500
| New | +$10.4M |
|
|
HOLX
21
DELISTED
Hologic
HOLX
| $11.4M | 1.56% |
+592,915
| New | +$12.4M |
|
|
MDVN
22
DELISTED
MEDIVATION, INC.
MDVN
| $10.2M | 1.38% |
+412,878
| New | +$10.4M |
|
23
Neurocrine Biosciences
NBIX
$18.7B
| $9.47M | 1.29% |
+707,990
| New | +$8.7M |
|
24
Incyte
INCY
$24.9B
| $9.27M | 1.26% |
+421,300
| New | +$9.2M |
|
|
QCOR
25
DELISTED
QUESTCOR PHARMA INC
QCOR
| $7.91M | 1.08% |
+173,928
| New | +$6.17M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Tekla Capital Management, which disclosed 60 positions worth $735M. Its ten largest holdings account for 56% of the portfolio.
Its largest position is Gilead Sciences: 1,504,712 shares worth $77.1M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, followed by Financials.
- Tekla Capital Management's largest Q2 2013 buy was Gilead Sciences: 1,504,712 shares worth $77.1M.
- Tekla Capital Management's ten largest holdings make up 56% of its $735M portfolio in Q2 2013.
- Tekla Capital Management disclosed 60 positions in Q2 2013, its first 13F filing on record.
Based on Tekla Capital Management's 13F filing for Q2 2013, filed 31 Jul 2013.